Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

Phase 4

Not yet recruiting

Conditions: Glucocorticoid-induced Osteoporosis

Interventions: Drug: Prolia®

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-19

Lead Sponsor: Amgen

Target Recruit Count: 100

Registration Number: NCT06588153

AMG 335 Expanded Access Program for IgG4-Related Disease

First Posted Date: 2024-09-10

Last Posted Date: 2024-09-10

Lead Sponsor: Amgen

Registration Number: NCT06590051

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Phase 1

Recruiting

Conditions: Cardiometabolic Disease

Interventions: Drug: AMG 513
Drug: Placebo

First Posted Date: 2024-09-05

Last Posted Date: 2024-11-14

Lead Sponsor: Amgen

Target Recruit Count: 80

Registration Number: NCT06585462

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸
Fomat Medical Research, Oxnard, California, United States

and more 1 locations

A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Phase 2

Not yet recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Inebilizumab
Drug: Blinatumomab

First Posted Date: 2024-08-26

Last Posted Date: 2024-12-06

Lead Sponsor: Amgen

Target Recruit Count: 50

Registration Number: NCT06570798

Locations: 🇺🇸
Homestead Associates In Research Inc, Homestead, Florida, United States
🇺🇸
Vida Medical Research, Hialeah, Florida, United States
🇺🇸
Vitaly Clinical Research, Miami, Florida, United States

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

Phase 3

Recruiting

Conditions: Prurigo Nodularis

Interventions: Drug: Rocatinlimab
Drug: Placebo

First Posted Date: 2024-07-30

Last Posted Date: 2024-12-18

Lead Sponsor: Amgen

Target Recruit Count: 460

Registration Number: NCT06527404

Locations: 🇺🇸
NorthShore University HealthSystem, Skokie, Illinois, United States
🇺🇸
Olympian Clinical Research - Tampa, Tampa, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 57 locations

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Phase 2

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Tarlatamab

First Posted Date: 2024-07-16

Last Posted Date: 2024-12-02

Lead Sponsor: Amgen

Target Recruit Count: 30

Registration Number: NCT06502977

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, Chongqing, China
🇨🇳
Harbin Meidical University Cancer Hospital, Harbin, Heilongjiang, China

and more 9 locations

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

Phase 1

Completed

Conditions: End-Stage Renal Disease (ESRD)

Interventions: Drug: Avacopan

First Posted Date: 2024-06-21

Last Posted Date: 2024-10-15

Lead Sponsor: Amgen

Target Recruit Count: 13

Registration Number: NCT06468826

Locations: 🇺🇸
Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

Phase 4

Recruiting

Conditions: Osteoporosis

Interventions: Drug: Prolia

First Posted Date: 2024-03-26

Last Posted Date: 2024-10-11

Lead Sponsor: Amgen

Target Recruit Count: 100

Registration Number: NCT06332014

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

and more 7 locations

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Recruiting

Conditions: Major Cardiovascular Event
Established Atherosclerotic Cardiovascular Disease

First Posted Date: 2024-03-06

Last Posted Date: 2024-12-05

Lead Sponsor: Amgen

Target Recruit Count: 7000

Registration Number: NCT06295679

Locations: 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
🇨🇳
Tianjin Huanhu Hospital, Tianjin, Tianjin, China
🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China

and more 85 locations

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Phase 3

Recruiting

Conditions: Extensive-Stage Small-Cell Lung Cancer
Small-Cell Lung Cancer

Interventions: Drug: Tarlatamab
Drug: Durvalumab

First Posted Date: 2024-01-18

Last Posted Date: 2024-12-18

Lead Sponsor: Amgen

Target Recruit Count: 550

Registration Number: NCT06211036

Locations: 🇺🇸
Franciscan Health Indianapolis, Indianapolis, Indiana, United States
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳
Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, China

and more 75 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy